• Álvaro Tamayo-Velasco, María Teresa Jiménez García, Alba Sánchez Rodríguez, Milagros Hijas Villaizan, Juana Carretero Gómez, and José Pablo Miramontes-González.
• Hematología Clínica, Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario de Valladolid, Valladolid, España. Electronic address: alvarotv1993@gmail.com.
• Med Clin (Barc). 2022 Jul 8; 159 (1): 273027-30.

Background And ObjectivesIn the pandemic caused by SARS-CoV-2, identifying which risk factors are associated with the most serious forms of the disease is important. Blood group A has been presented in various studies as a poor prognostic factor. The objective of this study was to evaluate whether patients with blood group A were associated with more important comorbidities, measured by the Charlson Index, which may explain their worse clinical evolution.Patients And MethodsA prospective and consecutive study examined 100 patients diagnosed with COVID-19 and admitted in March 2020. A multivariate linear regression model was used to evaluate the association of blood group A with the Charlson Index.ResultsPatients in group A had a higher Charlson Index (P=.037), rate of lymphopenia (P=.039) and thrombopenia (P=.014), and hospital mortality (P=.044). Blood group A was an independent factor associated with the Charlson Index (B 0.582, 95% CI 0.02-1.14, P=0.041).ConclusionsGroup A was independently associated with greater comorbidity, associated with an increase of 0.582 points in the Charlson Index compared to other blood groups. It was also associated with lower hospital mortality.Copyright © 2021 Elsevier España, S.L.U. All rights reserved.

16 keywords...

hide…